Trials / Not Yet Recruiting
Not Yet RecruitingNCT07459543
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Previously Untreated, Unresectable or Metastatic Melanoma in India.
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in untreated, unresectable or metastatic melanoma participants in India
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab + Relatlimab | Specified dose on specified days |
Timeline
- Start date
- 2026-11-15
- Primary completion
- 2029-05-26
- Completion
- 2029-05-28
- First posted
- 2026-03-09
- Last updated
- 2026-03-09
Locations
8 sites across 1 country: India
Source: ClinicalTrials.gov record NCT07459543. Inclusion in this directory is not an endorsement.